sb 203580 has been researched along with Hypercholesterolemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, J; Ma, H; Nisi, F; Song, X; Wang, D; Wei, W; Xiong, Y; Yang, L; Yu, F; Yuan, G; Zhou, H | 1 |
| Dimmeler, S; Haendeler, J; Langheinrich, AC; Sedding, D; Seeger, FH; Zeiher, AM | 1 |
2 other study(ies) available for sb 203580 and Hypercholesterolemia
| Article | Year |
|---|---|
Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis.
Topics: Adipocytes; Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Cell Adhesion; Cell Movement; Cell Proliferation; Chemokines; Collagen; Diet, High-Fat; Endothelial Progenitor Cells; Gene Expression Regulation; Humans; Hypercholesterolemia; Imidazoles; Kidney; Liver; Male; Mice; Mice, Knockout, ApoE; p38 Mitogen-Activated Protein Kinases; Plaque, Atherosclerotic; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Signal Transduction | 2020 |
Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Hypercholesterolemia; Imidazoles; Mesenchymal Stem Cells; Mice; Mice, Knockout; Neovascularization, Physiologic; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines | 2010 |